Bionure
- Company typePrivate
- Founded2009
- HeadquartersMenlo Park, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Bionure firmographics
Firmographics- Name
- Bionure
- Legal name
- BIONURE THERAPEUTICS, S.L.
- Website
- https://bionure.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Bionure industry classification
Industry- Product category
- Biopharmaceuticals (CNS Therapeutics)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Bionure is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Bionure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing Royalties: Out-licensing of drug candidates to pharmaceutical partners for late-stage development and commercialization. Revenue generated through upfront payments, milestone payments, and royalties on net sales. Example: BN201 licensed to Oculis in 2021 for Multiple Sclerosis, Glaucoma, and Acute Optic Neuritis indications.
- Investment Returns: As a biotech investment vehicle, Bionure generates returns through exit events including sale of portfolio companies, licensing deals, or IPO. Investment strategy focuses on Phase I/II CNS drug development with 2-5 year exit horizon.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Bionure product offering
Product offeringCore offering
Bionure is a late-preclinical biotechnology company developing peptidomimetic drug candidates (ACT01, ACT02, ACT03) and a proprietary therapeutic RNA platform for rare neurodegenerative diseases such as ALS, Rett syndrome, ataxia, and Huntington's disease. The company uses nanoparticle encapsulation technology to deliver therapeutics across the blood-brain barrier, and advances compounds from preclinical through Phase II before out-licensing to larger pharmaceutical partners for late-stage clinical development and commercialization.
Product overview
Bionure Therapeutics S.L. is a Barcelona-based biotechnology company founded in 2009, developing next-generation therapies for neurodegenerative diseases. The company operates a proprietary therapeutic RNA platform that produces a portfolio of products including chemical compounds (peptidomimetics) such as ACT01, ACT02, and ACT03. In 2023, the company strategically pivoted toward RNA-based therapeutics, leveraging nanoparticle encapsulation technology to deliver treatments directly to the brain. The product pipeline targets rare neurodegenerative diseases including ALS, Rett syndrome, ataxia, and Huntington's disease, with development stages ranging from preclinical through Phase II. Formerly focused on multiple sclerosis with the drug candidate BN201 (licensed to Oculis), the company's current programs are in preclinical stages.
Differentiator
Problem solved
Functional benefit
Products and services
- ACT01 (BN201)
- ACT02
- ACT03
- Therapeutic RNA Platform
Quantifiable outcome
- ACT-03 reduces gliosis in rat Rapid Kindling model of epilepsy and attenuates inflammation and barrier integrity loss in vitro
- +2 more outcomes
Companies that use Bionure
Customer profileSegments3 records
Ideal customer profiles2 records
Bionure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Bionure partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- OculiscoreSwiss pharmaceutical company Oculis licensed BN201 (ACT-01) in 2021 to complete Phase 2 and Phase 3 clinical trials in Acute Optic Neuritis, Multiple Sclerosis, and Glaucoma indications. This represents a key out-licensing partnership for late-stage development.
- Accure TherapeuticsmajorIn 2020, the scientific part of Bionure was merged with IProteos to form Accure Therapeutics, which has since been responsible for developing several nervous system therapy programs including neuroprotective treatments for multiple sclerosis, Parkinson's disease, and epilepsy.
- IDIBAPS - Hospital Clinic de BarcelonacoreSpin-off origin from IDIBAPS - Hospital Clinic de Barcelona, where founder Dr. Pablo Villoslada developed the core technology as principal investigator. First drug compound groups were patented from this institution before founding Bionure.
- Albert Zamora and Joan BigorracoreCo-founders alongside Dr. Pablo Villoslada in establishing Bionure as spin-off from IDIBAPS.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Bionure competitors and assessment
Company assessmentEmerging players
- Wave Life Sciences: Clinical-stage RNA therapeutics company with an explicit focus on CNS and rare neurological diseases using stereopure oligonucleotides. Comparable to Bionure's RNA + nanoparticle CNS delivery angle, but with multiple clinical-stage CNS assets.
- ProQR Therapeutics: RNA-editing / RNA-therapeutics biotech focused on rare genetic diseases including CNS and ophthalmology indications. Comparable modality (RNA therapeutics) and rare-disease focus overlapping with Bionure's ophthalmology and rare-disease programs.
Direct peers
- Oculis: Listed Swiss biotech focused on ophthalmology that licensed BN201 (ACT-01) from Bionure in 2021 for Phase 2/3 development in Acute Optic Neuritis, Multiple Sclerosis, and Glaucoma. Direct and most strategically connected peer given the active out-licensing relationship for Bionure's lead asset.
- Accure Therapeutics: CNS-focused biotech formed in 2020 from the merger of Bionure's scientific division with IProteos, continuing the development of neuroprotective programs for MS, Parkinson's disease, and epilepsy. Most directly comparable on indication and mechanistic focus, given that Accure effectively absorbed Bionure's research operations.
- Sage Therapeutics: CNS-focused biotech developing neuroactive therapeutics for neurology and psychiatry indications including rare epilepsies and neurodegeneration. Comparable on CNS / rare-disease positioning and a peptide-/small-molecule-style modality approach similar to Bionure's peptidomimetics.
- Denali Therapeutics: Biotech developing therapeutics for neurodegenerative diseases (ALS, Parkinson's, Huntington's, MS) using targeted biological modalities. Closely comparable therapeutic focus to Bionure's CNS/neurodegenerative pipeline targeting ALS, Rett syndrome, ataxia, and Huntington's disease.
- Anavex Life Sciences: Clinical-stage biotech developing small molecules for CNS indications including Rett syndrome, Parkinson's, Alzheimer's, and rare epilepsies. Closely comparable on rare CNS / neurodegenerative indication set that overlaps heavily with Bionure's ACT01/ACT02/ACT03 targets.
Broad incumbents
- Ionis Pharmaceuticals: Established antisense oligonucleotide (RNA-based) platform company with multiple approved and clinical-stage CNS/neurology programs. Comparable to Bionure's therapeutic RNA and oligonucleotide modalities and BBB delivery ambitions, though with far larger scale and pipeline.
- Biogen: Large established biopharmaceutical company with deep CNS franchise including MS (the indication of Bionure's former lead asset BN201). Represents the dominant incumbent in the same broad therapeutic space Bionure's pipeline targets.
- Alnylam Pharmaceuticals: Commercial-stage leader in RNA interference therapeutics with growing CNS pipeline. Directly comparable to Bionure's 2023-pivot therapeutic RNA platform strategy, but at vastly greater scale and with approved products.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Bionure social profiles
Digital presenceBionure compliance and trust
Trust signalCompliance3 records
Bionure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bionure leadership team
Management profileNumber of profiles
Profiles8 records
Bionure funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bionure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bionure
What does Bionure do?
Bionure is a late-preclinical biotechnology company developing peptidomimetic drug candidates (ACT01, ACT02, ACT03) and a proprietary therapeutic RNA platform for rare neurodegenerative diseases such as ALS, Rett syndrome, ataxia, and Huntington's disease. The company uses nanoparticle encapsulation technology to deliver therapeutics across the blood-brain barrier, and advances compounds from preclinical through Phase II before out-licensing to larger pharmaceutical partners for late-stage clinical development and commercialization.
Is Bionure a public or private company?
Bionure is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bionure founded?
Bionure was founded in 2009. It employs 1 to 10 people.
Where is Bionure based?
Bionure is headquartered in Menlo Park, United States, in the North America region.
How does Bionure make money?
Two revenue lines are on record. Licensing Royalties are the primary driver. The others are investment Returns.
Who are Bionure's main competitors?
Emerging players on record are Wave Life Sciences and ProQR Therapeutics. Direct peers are Oculis, Accure Therapeutics, Sage Therapeutics, Denali Therapeutics and Anavex Life Sciences. Broad incumbents are Ionis Pharmaceuticals, Biogen and Alnylam Pharmaceuticals.
Does Bionure have an API?
No public API is recorded for Bionure.
What industry is Bionure in?
Bionure's product category is Biopharmaceuticals (CNS Therapeutics). Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.